Jiangsu Cowin Biotech Co. Ltd. A

Kangwei Century released its 2026 interim report. In the first half of the year, the company's operating revenue was 113 million yuan, up 29.7% year on year. Net profit attributable to the parent company changed from a loss of 55.91 million yuan in the same period last year to a loss of 35.18 million yuan, with the loss narrowing. Net profit attributable to the parent company after deducting non-recurring items changed from a loss of 66.56 million yuan in the same period last year to a loss of 45.39 million yuan, with the loss narrowing. Net operating cash flow was negative 28.39 million yuan, up 42.8% year on year. Earnings per share were negative 0.3128 yuan. In the second quarter, the company's operating revenue was 54.02 million yuan, up 22.5% year on year. Net profit attributable to the parent company changed from a loss of 33.17 million yuan in the same period last year to a loss of 19.83 million yuan, with the loss narrowing. Net profit attributable to the parent company after deducting non-recurring items changed from a loss of 37.79 million yuan in the same period last year to a loss of 24.8 million yuan, with the loss narrowing. Earnings per share were negative 0.1763 yuan. As of the end of the second quarter, the company's total assets were 1.486 billion yuan, down 0.7% from the end of the previous year. Net assets attributable to the parent company were 1.318 billion yuan, down 2.4% from the end of the previous year. In the interim report, the company noted that it continues to focus on independent research and development of core molecular detection technologies, and has established multiple technology platforms covering raw material enzymes, nucleic acid preservation, and sample pre-processing. It has developed more than 700 core products and provides a range of testing services around high-throughput sequencing platforms, forming an integrated layout.

Jiangsu Jianwei Diagnostic Technology Co., Ltd., a wholly-owned subsidiary of Kangwei Century, has independently developed a Mycoplasma pneumoniae nucleic acid and drug-resistance mutation site detection kit using fluorescent PCR. The kit recently obtained a Class III Medical Device Registration Certificate for in vitro diagnostic reagents from the National Medical Products Administration, valid until August 16, 2031. The product is used for in vitro qualitative detection of Mycoplasma pneumoniae DNA and its antibiotic resistance mutation sites 23S rRNA 2063 A to G and 23S rRNA 2064 A to G in human throat swab samples. Using fluorescent PCR technology, it can simultaneously detect the Mycoplasma pneumoniae P1 gene nucleic acid and its macrolide antibiotic resistance mutation sites. A single sampling and a single test can confirm infection and provide drug resistance information at the same time, helping to avoid failure of empirical medication and improve treatment success rates. The product is compatible with mainstream fluorescent quantitative PCR platforms and is suitable for a wide range of settings, including fever clinics, respiratory departments, pediatrics, and primary healthcare institutions. As of the announcement date, this product is the company's fifth Class III registration certificate for respiratory disease detection, further enriching its product pipeline in the field of respiratory pathogen detection. It marks important progress in the company's integrated molecular diagnostic product layout of infection diagnosis plus drug resistance testing, and is expected to enhance the company's competitiveness in the molecular diagnostic market for respiratory infections.